Pacific Biosciences of California Inc (PACB)
Industry Medical Devices
This stock can be held in an Investment ISA and an Investment Account
Sell
$0.9925
Buy
$0.9926
$-0.0674 (-6.36%)
Pacific Biosciences of California Inc is a biotechnology company. It is engaged in design, development, and manufacture of sequencing system to help scientists resolve genetically complex problems.
Prices updated at 16 May 2025, 16:07 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| 93m | 79m | 91m | 79m | 131m | 128m | 201m | 154m | |
| 35m | 25m | 35m | 33m | 59m | 49m | 53m | 37m | |
| -90m | -101m | -101m | -104m | -178m | -305m | -310m | -291m | |
| -96.06 | -128.44 | -110.62 | -132.31 | -136.51 | -237.58 | -154.78 | -188.73 | |
| -92m | -103m | -84m | 29m | -181m | -314m | -307m | -310m | |
| -81m | -93m | -72m | 39m | -251m | -282m | -277m | -243m | |
| Sales, General and administrative | 59m | 63m | 75m | 73m | 124m | 161m | 170m | 175m |
| Interest expenses | 3m | 2m | 3m | 267,000 | 13m | 15m | 14m | 13m |
| Provision for income taxes | - | - | - | - | -94m | - | -11m | 316,000 |
| Operating expenses | 124m | 126m | 135m | 137m | 237m | 354m | 363m | 328m |
| Income before taxes | -92m | -103m | -84m | 29m | -275m | -314m | -318m | -310m |
| Net income available to common shareholders | -92m | -103m | -84m | 29m | -181m | -314m | -307m | -310m |
| -0.87 | -0.76 | -0.55 | 0.18 | -0.89 | -1.4 | -1.21 | -1.13 | |
| Net interest income | -3m | -2m | -3m | -267,000 | -13m | -15m | -14m | -13m |
| Advertising and promotion | - | - | - | - | - | - | - | - |
| Net investment income, net | - | - | - | - | - | - | - | - |
| Realised capital gains (losses), net | - | - | - | - | - | - | - | - |
| Total benefits, claims and expenses | - | - | - | - | - | - | - | - |
| Earnings per share (diluted) | -0.87 | -0.76 | -0.55 | 0.17 | -0.89 | -1.4 | -1.21 | -1.59 |
| Free cash flow per share | -0.7242 | -0.5559 | -0.5399 | 0.0922 | -0.4721 | -1.1157 | -1.1262 | -0.8855 |
| Book value/share | 0.8721 | 0.8778 | 0.3332 | 0.6734 | 3.8049 | 2.7663 | 2.8525 | 1.539 |
| Debt equity ratio | 0.158357 | 0.128519 | 0.764135 | 0.112274 | 1.196021 | 1.66592 | 1.31733 | 1.307572 |
Balance sheet
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Current assets | 102m | 132m | 81m | 356m | 1,101m | 852m | 742m | 496m |
| Current liabilities | 29m | 27m | 49m | 39m | 72m | 263m | 95m | 66m |
| Total capital | 100m | 129m | 55m | 335m | 1,687m | 1,460m | 1,594m | 1,154m |
| Total debt | 14m | 15m | 62m | 42m | 954m | 948m | 934m | 672m |
| Total equity | 86m | 114m | 55m | 335m | 791m | 563m | 701m | 507m |
| Total non current liabilities | - | - | - | - | - | - | - | - |
| Loans | 14m | 15m | - | - | 896m | 897m | 892m | 647m |
| Total assets | 144m | 170m | 148m | 414m | 2,007m | 1,767m | 1,746m | 1,260m |
| Total liabilities | - | - | - | - | - | - | - | - |
| Cash and cash equivalents | 17m | 19m | 30m | 82m | 461m | 325m | 180m | 55m |
| Common stock | 116m | 150m | 153m | 192m | 221m | 227m | 268m | 294m |
Cash flow
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash at beginning of period | 17m | 21m | 23m | 34m | 86m | 466m | 328m | 183m |
| Cash dividends paid | - | - | - | - | - | - | - | - |
| -78m | -68m | -81m | 18m | -117m | -280m | -268m | -212m | |
| Investments (gains) losses | -2m | -38m | 62m | -219m | -679m | 116m | 5m | 124m |
| 17m | 23m | 34m | 86m | 466m | 328m | 180m | 55m | |
| Net income | - | - | - | - | - | - | - | - |
| -68m | -66m | -78m | 20m | -111m | -263m | -259m | -206m | |
| -10m | -2m | -3m | -1m | -6m | -17m | -9m | -6m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
